Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Baricitinib in Severe or Very Severe Alopecia Areata
NCT03570749Phase 3Completed
- Sponsor
- Eli Lilly and Company
- Start
- Sep 2018
- Primary completion
- Feb 2021
- Modality
- Recombinant Proteins and Enzymes, Small Molecules, Antibody-Based Therapeutics
- Countries
- 5
01
Overview
Phase 3, randomised, double-blind trial of baricitinib in alopecia areata (16 arms), sponsored by Eli Lilly and Company. Primary endpoints: Percentage of Participants Achieving Severity of Alopecia Tool (SALT) <= 20 at 36 weeks and Percent Change From Baseline in SALT Score at 52 weeks. Started Sep 2018; status: completed.
02
Drugs
baricitinib
03
Conditions
alopecia areata
Beyond the preview
Go deeper on NCT03570749.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03570749.